Descripción de la empresa
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the identification of novel targets for cancer drug development and the subsequent development and commercialization of oncology therapies. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, a domain characterized by high research and development expenditures aimed at delivering innovative treatments for critical medical conditions. As of the latest reported data, Lixte Biotechnology Holdings, Inc. maintains a market capitalization of $24.80M and reports a net income of $-6,078,593 over the trailing twelve-month period, while the employee count is listed as N/A. The combination of a relatively modest market cap of $24.80M and negative annual revenue figures indicates that the company is in an early-stage growth phase where capital is predominantly allocated toward advancing clinical trial programs rather than generating immediate sales revenue or establishing a mature profit-generating infrastructure.
Salud financiera
Over the trailing twelve-month period, the company recorded N/A for revenue, reported a net income of $-6,078,593, and has N/A for EBITDA, a financial profile typical for clinical-stage entities where operational expenses significantly outweigh current sales. The substantial gap between the reported revenue of N/A and the negative net income of $-6,078,593 reveals a cost structure heavily weighted toward research, development, and clinical trial costs that have not yet been offset by commercial income. The company's free cash flow stands at $-2,838,636, indicating a continuous burn rate that necessitates ongoing capital raises to maintain operations and advance its product candidates like LB-100. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which reflects the fact that the company has not yet achieved commercial scale where margins are realized. The balance sheet shows a cash position of $5.11M against total debt of $1.03M, resulting in a Debt to Equity ratio of 9.44, which suggests the company relies primarily on equity financing rather than debt to fund its activities. Despite the high Debt to Equity ratio of 9.44, the Current Ratio of 3.88 indicates strong short-term liquidity, suggesting the firm possesses sufficient current assets to cover its short-term liabilities. The Return on Equity is -102.0% and the Return on Assets is -46.0%, metrics that mathematically reflect the significant losses incurred relative to the shareholders' equity and total assets, highlighting that management effectiveness is currently measured by the preservation of cash rather than the generation of returns.
Evaluación de valoración
Lixte Biotechnology Holdings, Inc. reports N/A for both the P/E Ratio (TTM) and the Forward P/E, a status that is standard for companies with negative earnings and implies that traditional earnings-based valuation multiples are not applicable at this stage of the company's lifecycle. The price-to-book ratio is recorded at 3.16, indicating that the market values the company at more than three times its book value, which often reflects the intrinsic value of the company's intellectual property and pipeline potential rather than current asset holdings. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA are both listed as N/A, suggesting that investors must rely on cash burn rates and pipeline milestones rather than traditional sales or earnings multiples to assess the company's relative value. The stock has traded between a 52-week low of $0.64 and a 52-week high of $6.26, and without a specific current price provided in the data, the valuation context remains anchored within this wide volatility range of $0.64 to $6.26. The Beta is listed as N/A, meaning that the historical volatility data required to calculate the stock's sensitivity to broader market movements is not currently available for analysis.
Growth & Income
The company reports N/A for Revenue Growth (YoY) and Earnings Growth (YoY), figures that are expected to remain absent until the company transitions from clinical development to commercial sales and begins generating positive earnings growth. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available financial resources are reinvested directly into research and development activities rather than distributed to shareholders. The absence of a dividend payout ratio of 0.0% is consistent with a non-dividend payer profile where the primary strategy is to fuel organic growth through the advancement of the LB-100 candidate and other therapeutic programs. The overall growth and income profile is defined by a high-revenue-burn model where growth is measured in clinical milestones and regulatory progress rather than traditional financial statement expansion or dividend yield generation.